Loading
Distinct shells carrying a filed role for this person — not every shell they have ever touched.
Of those vehicles, the ones that closed a merger.
Announced but not closed, and still hunting.
No closed vehicle here has both a stored price and a filed trust value to score it against.
2 liquidated — weigh against the wins.
2 vehicles on file, newest listing first
3 people on two or more of them
Kishan Mehta (also known as Kishen Mehta) is a financial industry professional with over 15 years of experience, currently serving as a Portfolio Manager at Suvretta Capital Management, LLC, where he manages the Averill strategy with a focus on the healthcare and biotechnology sectors. Based in the New York City metropolitan area, Mehta earned his education at New York University's Leonard N. Stern School of Business. His career in finance has centered on investment management and biotechnology investing, establishing him as a specialist in identifying and evaluating opportunities within the life sciences industry. He is also associated with Montanova Capital, LLC, according to his LinkedIn profile.
In 2021, Mehta partnered with prominent investor Chamath Palihapitiya to launch four biotech-focused special purpose acquisition companies under the Social Capital Suvretta Holdings Corp. banner (SPACs I through IV). Mehta served as President and a director of each of the four SPACs, while Palihapitiya acted as chairman and CEO. The sponsor entity for these SPACs was managed jointly by Palihapitiya and Mehta, with Mehta also holding the role of manager. Social Capital Suvretta Holdings Corp. I (DNAA) raised $220 million in its June 2021 IPO after upsizing from 20 million to 22 million Class A shares priced at $10 each, while Social Capital Suvretta Holdings Corp. IV (DNAD) filed for a $200 million IPO, also targeting the biotech sector. The SPACs were incorporated in the Cayman Islands and maintained offices at 2850 W. Horizon Ridge Parkway, Suite 200, Henderson, Nevada, with a contact number of (650) 521-9007. Mehta is credited as the founder of Social Capital Suvretta Holdings Corp. IV, which he established in 2021.
Beyond his SPAC and portfolio management roles, Mehta has held board positions at multiple publicly traded and private biopharmaceutical companies. He was appointed to the Board of Directors of Biohaven Pharmaceutical Holding Co Ltd (BHVN) in June 2021, where he served as a director. He was also appointed to the Board of Directors of Benitec Biopharma, further extending his governance footprint in the biotechnology space. SEC filings indicate that Mehta has held ownership or reporting relationships with at least nine companies, including Biohaven, Social Capital Suvretta Holdings Corp. I (DNAA), and Social Capital Suvretta Holdings Corp. III (DNAC), reflecting his deep involvement across the Social Capital Suvretta SPAC platform and related biotech investments. His mailing address on SEC filings is listed as New York, NY 10019.
Mehta's track record is defined by his specialized expertise at the intersection of finance and biotechnology, combining his role as a healthcare-focused portfolio manager at Suvretta with his partnership alongside one of the SPAC market's most prominent figures. The Social Capital Suvretta SPACs were specifically designed to target businesses operating in the biotechnology industry, with Corp. I focusing on the neurology subsector, leveraging Mehta's domain knowledge to source and evaluate potential acquisition targets. His dual roles as both an investment manager and a corporate director across multiple biopharma boards position him as a key figure in the biotech investment landscape, with his career spanning portfolio management, SPAC sponsorship, and active board-level governance at life sciences companies.
This record is keyed to SEC CIK 0001850520 — the identifier this person files under in their own name. Every vehicle above is a filing made under that CIK, so “the same person on two shells” is a fact about an SEC identifier rather than about a name that happens to match.
Roles are the strings the filings used, in the order they were filed. Nothing on this page ranks them, infers seniority, or offers a reason why any two of these names recur — a recurrence is a count, and the filings that produced it are linked beside every row. We also hold 63 institutional-holder rows on these vehicles, under 22 distinct name strings, and none of them is counted across vehicles: that table has no CIK column, and matching holders by name would merge firms that are not the same firm.